Avogadro was founded by Dr. Christopher R. Shepard in 2016 and was incubated by SBE. The company is advancing its Phase 2/3 Bazlitoran package into non-alcoholic steatohepatitis (NASH) and fibrosis. Bazlitoran is the first targeted inhibitor with comprehensive biological activity and biomarkers for NASH and fibrosis. The company's investors include SBE and Nest Bio Ventures.